TRADJENTA Drug Patent Profile

Which patents cover Tradjenta, and when can generic versions of Tradjenta launch?

Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and eighty-one patent family members in forty-one countries.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the linagliptin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tradjenta

A generic version of TRADJENTA was approved as linagliptin by SUNSHINE on August 31^st, 2021.

Summary for TRADJENTA

International Patents:	381
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRADJENTA

Paragraph IV (Patent) Challenges for TRADJENTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRADJENTA	Tablets	linagliptin	5 mg	201280	11	2015-05-04

US Patents and Regulatory Information for TRADJENTA

TRADJENTA is protected by ten US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	11,911,388
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	10,034,877*PED				Y
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	8,883,805*PED				Y
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	9,486,526*PED				Y

International Patents for TRADJENTA

When does loss-of-exclusivity occur for TRADJENTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

Denmark

Eurasian Patent Organization

Japan

Singapore

Slovenia

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRADJENTA around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	358617
Hungary	S1100028
China	102186466
Uruguay	32030	"TRATAMIENTO PARA DIABETES EN PACIENTES INAPROPIADOS PARA TERAPIA CON METFORMINA"
Malaysia	170728	TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY

Supplementary Protection Certificates for TRADJENTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	CR 2014 00065	Denmark		PRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110830
1532149	CA 2011 00030	Denmark
1084705	SPC/GB14/084	United Kingdom		PRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830
1084705	C01084705/02	Switzerland		PRODUCT NAME: VILDAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 57834 30.04.2008
1532149	SPC/GB12/006	United Kingdom		PRODUCT NAME: LINAGLIPTIN, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/11/707/001 20110830; UK EU/1/11/707/002 20110830; UK EU/1/11/707/003 20110830; UK EU/1/11/707/004 20110830; UK EU/1/11/707/005 20110830; UK EU/1/11/707/006 20110830; UK EU/1/11/707/007 20110830; UK EU/1/11/707/008 20110830; UK EU/1/11/707/009 20110830; UK EU/1/11/707/010 20110830; UK EU/1/11/707/011 20110830

TRADJENTA (Linagliptin): Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What is the current market position of TRADJENTA?

TRADJENTA (linagliptin) is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor approved by the FDA in May 2017 for type 2 diabetes management. It is marketed by Boehringer Ingelheim and Eli Lilly. As of 2023, it maintains a significant share of the DPP-4 inhibitor market, estimated at approximately 15% globally [1].

The drug targets a multi-billion dollar market expected to grow as type 2 diabetes prevalence increases. The global diabetes market was valued at USD 100 billion in 2022 and is projected to reach USD 144 billion by 2030 (CAGR 4.2%) [2].

How does TRADJENTA compare to its competitors?

TRADJENTA's primary competition includes Januvia (sitagliptin), Onglyza (saxagliptin), and Nesina (alogliptin). Key differentiator:

• Pharmacokinetics: Linagliptin does not require dose adjustment in renal impairment due to exclusive hepatic clearance, unlike sitagliptin which needs dose adjustment [3].

• Efficacy & Safety: Comparable glycemic control, with similar side effect profiles focused on mild hypoglycemia and nasopharyngitis.

• Pricing: Slightly higher than Januvia but justified by less frequent dosing and renal safety profile.

Market share distribution (2022):

Drug	Share (%)	Key strengths
Januvia	45%	Well-established, broad use
TRADJENTA	15%	Renal safety, once-daily dosing
Onglyza	10%	Alternative mechanism, cardiovascular data
Nesina	10%	Competing agent, similar profile

What are the key revenue drivers and growth drivers?

Revenue drivers include:

• Market penetration: Expanding approval in emerging markets such as China, India, and Southeast Asia.

• Label expansions: Potential approval for triple therapy or complications such as non-alcoholic fatty liver disease (NAFLD).

• Brand loyalty: Physicians favor linagliptin for target patients with renal impairments due to safety profile.

Growth drivers:

• Increasing global prevalence of type 2 diabetes fueled by lifestyle factors and aging population.
• Shifting treatment guidelines favoring early DPP-4 inhibitor use for certain patient groups.
• The rising number of combination therapies incorporating linagliptin.

Projected revenues from TRADJENTA are expected to grow at around 8-10% annually through 2025, driven by market expansion and increased adoption [4].

What are the manufacturing and patent considerations?

• Patent life: Linagliptin's composition patent expires in 2028 in the US, with some patents extending to 2030-2035 in key markets [5].

• Manufacturing: Boehringer Ingelheim maintains robust manufacturing capacity. The drug’s synthesis process involves a streamlined chemical route, reducing costs.

• Generics: Launch of generic linagliptin anticipated post-patent expiration, potentially affecting pricing and market share.

What are the regulatory risks and clinical pipeline prospects?

• Regulatory risks: Delays or rejections in key markets. Additional data may be required for expanded indications.

• Pipeline: Currently, no major pipeline expansion for linagliptin. However, similar DPP-4 inhibitors are being studied for cardiovascular and hepatic indications, which could affect the competitive landscape.

Investment considerations:

• Stable revenue stream from existing sales.
• Growth prospects driven by geographic expansion and combination therapies.
• Patent expirations pose a competitive threat from generics within the next five years.
• Partnership with Lilly supports marketing and distribution scale.

Key financial metrics:

Metric	2022 Data	Notes
Global sales	USD 600 million	Approximate, based on market share estimates
R&D expenditure	USD 50 million	Focused on pipeline and post-approval studies
Gross margin	70%	Industry-standard for branded pharmaceuticals

Summary:

TRADJENTA is a mature product with steady sales, benefiting from its renal safety profile and ease of use. Growth leverages geographic expansion, combination therapies, and evolving treatment guidelines. Patent expiration in 2028 creates near-term risk of generic competition that could impact pricing and revenue.

---

Key Takeaways

• TRADJENTA holds a stable position in the DPP-4 inhibitor market, with annual revenues in the hundreds of millions USD.
• Competition remains intense, with Januvia maintaining the largest market share.
• Its pharmacokinetic profile makes it attractive for patients with renal impairment.
• Patent expiration timelines are critical for assessing future revenue impacts.
• The global diabetes epidemic supports long-term growth prospects.

---

FAQs

Q1: How does linagliptin differ from other DPP-4 inhibitors?
Linagliptin does not require dose adjustments in renal impairment, unlike other agents like sitagliptin, making it suitable for high-risk patients.

Q2: What are the main risks to investment in TRADJENTA?
Patent expiration in 2028, potential generic entry, and competitive pressure from other oral antidiabetics.

Q3: Are there regulatory hurdles for TRADJENTA's expansion?
Possible hurdles include the need for additional cardiovascular or hepatic data to support new indications or label extensions.

Q4: What is the outlook for TRADJENTA's market share?
Expected to remain stable or grow modestly due to its renal safety profile and geographic expansion.

Q5: How might new therapies impact TRADJENTA's sales?
Emergence of SGLT2 inhibitors and GLP-1 receptor agonists, which have shown cardiovascular benefits, may reduce DPP-4 inhibitor market share over time.

---

References

[1] Statista. (2023). Global DPP-4 inhibitor market share.
[2] Fortune Business Insights. (2022). Diabetes drugs market forecast.
[3] U.S. FDA. (2017). TRADJENTA (linagliptin) prescribing information.
[4] EvaluatePharma. (2022). 2022 World Preview: Trends in diabetes therapy.
[5] Pharmaceutical Patent Data. (2023). Linagliptin patent timeline.